Danny Vesprini | Radiation Oncology

Dr. Danny Vesprini, MD

Claim this profile

Sunnybrook Odette Cancer Centre

Studies Prostate Cancer
Studies Prostate Adenocarcinoma
6 reported clinical trials
7 drugs studied

Area of expertise

1Prostate Cancer
Danny Vesprini, MD has run 5 trials for Prostate Cancer. Some of their research focus areas include:
BRCA1 positive
BRCA2 positive
Stage III
2Prostate Adenocarcinoma
Danny Vesprini, MD has run 1 trial for Prostate Adenocarcinoma.

Affiliated Hospitals

Image of trial facility.
Sunnybrook Odette Cancer Centre
Image of trial facility.
Sunnybrook Health Sciences Center

Clinical Trials Danny Vesprini, MD is currently running

Image of trial facility.

Rectal Hydrogel Spacer

for Prostate Cancer

There are several single institutional series that have reported their experience with salvage radiotherapy options that include EBRT, LDR and HDR brachytherapy. Gastrointestinal (GI) toxicity with salvage radiotherapy range between14-58%, respectively for patients undergoing re-irradiation. There is a concern for an increased risk of fistula development in these patients who receive second course of radiation. Hypofractionation using SABR has been utilized in the re-irradiation setting for prostate cancer with good tumor control and toxicity outcomes. In order to decrease the rectal toxicity, dose to the rectum should be kept as low as possible. Several techniques can be used to achieve this: tighter dosimetric dose painting, better patient or organ immobilization or use of a biodegradable gel. The Investigators ropose a phase I study to assess placement of a hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
Recruiting1 award N/A
Image of trial facility.

Targeted Radiotherapy

for Prostate Cancer

This study is a single centre feasibility trial. The trial will recruit men with intermediate risk localised prostate cancer who will all receive targeted dose (escalated/de-escalated dose directed by MRI) 5 fraction SBRT to the prostate. Trial Objectives are: 1. Primary To develop a 5 fraction de-escalated dose SBRT protocol capable of reducing side effects 2. Secondary * To assess levels of acute GU and GI toxicity (CTCAE) * To assess levels of late GU and GI toxicity (CTCAE) * To assess late sexual quality of life (expanded EPIC, IIEF-5) * To assess biochemical relapse-free survival at 2
Recruiting1 award N/A10 criteria

More about Danny Vesprini, MD

Clinical Trial Related7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Danny Vesprini, MD has experience with
  • Stereotactic Ablative Body Radiation
  • MR Linac Delivered Radiotherapy
  • SBRT
  • MS3TMRI
  • TRUS Guided Biopsy
  • SABR

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Danny Vesprini, MD specialize in?
Is Danny Vesprini, MD currently recruiting for clinical trials?
Are there any treatments that Danny Vesprini, MD has studied deeply?
What is the best way to schedule an appointment with Danny Vesprini, MD?
What is the office address of Danny Vesprini, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security